RxDoctor Payments Data

Charles Keller, MD

Ophthalmology · Orange, CANPI 1558324392

Payments from drug & device makers

$7,059in general payments, 2019–2025

Across 87 payments — averaging $81.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$5K
  • Carl Zeiss Meditec, Inc.$475
  • AbbVie$445
  • Johnson & Johnson Surgical Vision, Inc.$148
  • Ocular Therapeutix, Inc.$91
  • Aerie Pharmaceuticals, Inc.$91
  • plus $647 from 12 others

What the payments were for

  • Consulting fees$4006%
  • Speaking & faculty fees$4,67566%
  • Travel & lodging$120%
  • Food & beverage$1,95428%
  • Gifts$170%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,059 in reported general payments places this provider in the 75th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$203,861
Medicare patients
424
Services billed
1,605

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine22$29,596
ProlensaBromfenac Sodium53$17,364
LumiganBimatoprost14$10,369
Prednisolone Acetate197$8,775
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol29$5,337
Latanoprost324$4,150
FlarexFluorometholone Acetate28$3,637
Travoprost15$2,019
Timolol Maleate28$1,919
Loteprednol Etabonate12$1,731
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat98$1,272
Fluorometholone19$1,087
Tobramycin-DexamethasoneTobramycin/Dexamethasone22$934
Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim109$851
MoxifloxacinMoxifloxacin Hcl20$599

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$445$39,96536 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate$89$19,09565 claims
Eyevance Pharmaceuticals LLCFlarex$23$3,63728 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in Orange

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →